Welcome to Multibagg AI
Log in to access personalized features
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY24
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Anupam Rasayan India Ltd (ANURAS) is currently trading at 1,253.90 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Anupam Rasayan India Limited is a leading Indian company specializing in custom synthesis and manufacturing of specialty chemicals, catering to agrochemical, personal care, and pharmaceutical industries. The company showcased significant financial performance this quarter with a consolidated revenue of ₹7,392 Mn, marking a year-on-year growth of 149% and achieving over a 50% revenue growth in FY26. Strategic acquisitions and contracts, such as the Elementium LOI for battery chemicals, have positioned Anupam Rasayan for substantial long-term growth in specialty chemicals markets. The company has a robust order book of ₹14,646 crore, reflecting major contract wins and strong revenue visibility over the next 5-7 years. With a sustainable business model and operational excellence, Anupam Rasayan continues to experience a notable improvement in profitability and operational efficiencies, reflecting resilient growth across global markets.
Over the past 52 weeks, Anupam Rasayan India Ltd has traded between a low of ₹600.95 and a high of ₹1,405.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Anupam Rasayan India Ltd has a market capitalization of approximately 14,149.64. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Anupam Rasayan India Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 82.25 and operates in the Chemicals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 14,149.64 Cr, Anupam Rasayan India Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Anupam Rasayan India Ltd operates in the Chemicals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Anupam Rasayan India Ltd is 82.25. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Anupam Rasayan is acquiring 100% of Doriath S.à r.l. and 15% of Batam S.à r.l., both of which are based in Luxembourg.
Anupam Rasayan India Limited has scheduled its next board meeting for February 14, 2026.
The 10,000 crore Biopharma Shakti scheme promotes domestic production of biologics and biosimilars, which increases demand for the pharmaceutical intermediates and key starting materials (KSMs) manufactured by Anupam Rasayan.
Investor Presentation
Investor presentation: consolidated 9M FY26 revenue ₹17,297 mn and EBITDA ₹4,024 mn; Q3 revenue ₹5,124 mn and EBITDA ₹1,296 mn; signed definitive agreement to acquire Jayhawk Fine Chemicals (US).
Earnings & Acquisition
Anupam Rasayan reports Q3 FY26 consolidated revenue ₹5,145mn (+33% YoY), EBITDA ₹1,296mn (+7%), PAT ₹606mn (+12%) and has signed a definitive agreement to acquire Jayhawk Fine Chemicals (US).
Financial Results
Anupam Rasayan reported Q3 FY26 consolidated revenue of ₹5,145m (+33% YoY), EBITDA ₹1,296m (+7%), PAT ₹606m (+12%) and signed a definitive agreement to acquire Jayhawk Fine Chemicals (US).
Financial Results
Board of Anupam Rasayan India Ltd on Feb 14, 2026 approved standalone and consolidated unaudited financial results for the quarter and nine months ended Dec 31, 2025 (limited review reports enclosed); results show higher revenue and PBT vs prior year.
Unaudited Financial Results
Board of Anupam Rasayan India Ltd approved unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025; limited review reports were enclosed with no material findings.
Board Meeting Outcome
Board of Anupam Rasayan India Ltd approved unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (Q3 total revenue INR 4,063.20m; Q3 PBT INR 427.40m; 9M revenue INR 13,224.65m; 9M PBT INR 1,362.55m); limited review reports enclosed.
Bearish
0
Neutral
6
Bullish
8
Bearish
24
Neutral
6
Bullish
16
Bearish
24
Neutral
0
Bullish
8
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
454.30 | 16,473 Cr | 44.41 | 2.88 | 0.22 | 5.09 | 5.85 | 3.23 | |
3625.00 | 15,728 Cr | 43.02 | 4.15 | 0.55 | 9.90 | 13.43 | 4.93 | |
1495.00 | 15,453 Cr | 34.99 | 5.27 | 0.50 | 14.85 | 19.95 | 13.41 | |
1242.85 | 14,150 Cr | 82.25 | 4.43 | 0.06 | 4.73 | 9.37 | 3.94 | |
4395.00 | 13,463 Cr | 34.42 | 5.43 | 0.25 | 16.37 | 21.90 | 14.91 | |
965.00 | 12,820 Cr | 57.24 | 5.51 | 0.00 | 8.36 | 10.91 | 7.57 | |
2804.50 | 10,975 Cr | 36.47 | 8.85 | 0.18 | 21.52 | 19.32 | 9.69 |
Anupam Rasayan India Limited is a leading Indian company specializing in custom synthesis and manufacturing of specialty chemicals, catering to agrochemical, personal care, and pharmaceutical industries.
The company showcased significant financial performance this quarter with a consolidated revenue of ₹7,392 Mn, marking a year-on-year growth of 149% and achieving over a 50% revenue growth in FY26.
Strategic acquisitions and contracts, such as the Elementium LOI for battery chemicals, have positioned Anupam Rasayan for substantial long-term growth in specialty chemicals markets.
The company has a robust order book of ₹14,646 crore, reflecting major contract wins and strong revenue visibility over the next 5-7 years.
With a sustainable business model and operational excellence, Anupam Rasayan continues to experience a notable improvement in profitability and operational efficiencies, reflecting resilient growth across global markets.
Chemicals
Chemicals - Speciality - Large
14,150 Cr
Low Risk
82.3
44.8
2.9
4.4
1,405.00
600.95
Sales CAGR
Profit CAGR
ROE
ROCE
